{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,19]],"date-time":"2025-10-19T21:19:18Z","timestamp":1760908758842},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T00:00:00Z","timestamp":1337558400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"published-print":{"date-parts":[[2012,12]]},"DOI":"10.1186\/1471-2407-12-186","type":"journal-article","created":{"date-parts":[[2012,5,21]],"date-time":"2012-05-21T16:26:29Z","timestamp":1337617589000},"source":"Crossref","is-referenced-by-count":14,"title":["Imatinib-induced liver cirrhosis in a patient with advanced gastrointestinal stroma tumor (GIST)"],"prefix":"10.1186","volume":"12","author":[{"given":"Christoph","family":"Seidel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Fenner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florian","family":"L\u00e4nger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heike","family":"Bantel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arnold","family":"Ganser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Viktor","family":"Gr\u00fcnwald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2012,5,21]]},"reference":[{"key":"3175_CR1","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1016\/j.ejca.2010.02.014","volume":"46","author":"A Le Cesne","year":"2010","unstructured":"Le Cesne A, Blay JY, Bui BN, Bouch\u00e9 O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O: Phase II study of oral masitinib mesilate in imatinib-na\u00efve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST). Eur J Cancer. 2010, 46: 1344-1351. 10.1016\/j.ejca.2010.02.014.","journal-title":"Eur J Cancer"},{"key":"3175_CR2","doi-asserted-by":"publisher","first-page":"1656","DOI":"10.1038\/sj.bjc.6603797","volume":"96","author":"B Nilsson","year":"2007","unstructured":"Nilsson B, Sj\u00f6lund K, Kindblom LG, Meis-Kindblom JM, B\u00fcmming P, Nilsson O, Andersson J, Ahlman H: Adjuvant imatinib treatment improves recurrence-free survival in patients with high-risk gastrointestinal stromal tumours (GIST). Br J Cancer. 2007, 96: 1656-1658. 10.1038\/sj.bjc.6603797.","journal-title":"Br J Cancer"},{"key":"3175_CR3","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1016\/S0140-6736(09)60500-6","volume":"373","author":"RP Dematteo","year":"2009","unstructured":"Dematteo RP, Ballman KV, Antonescu CR, Maki RG, Pisters PW, Demetri GD, Blackstein ME, Blanke CD, von Mehren M, Brennan MF, Patel S, McCarter MD, Polikoff JA, Tan BR, Owzar K, American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study Team: Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial. Lancet. 2009, 373: 1097-1104. 10.1016\/S0140-6736(09)60500-6.","journal-title":"Lancet"},{"key":"3175_CR4","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1056\/NEJMoa022457","volume":"348","author":"SG O'Brien","year":"2003","unstructured":"O'Brien SG, Guilhot F, Larson RA, Gathmann I, Baccarani M, Cervantes F, Cornelissen JJ, Fischer T, Hochhaus A, Hughes T, Lechner K, Nielsen JL, Rousselot P, Reiffers J, Saglio G, Shepherd J, Simonsson B, Gratwohl A, Goldman JM, Kantarjian H, Taylor K, Verhoef G, Bolton AE, Capdeville R, Druker BJ, IRIS Investigators: Imatinib compared with interferon and lowdose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003, 348: 994-1004. 10.1056\/NEJMoa022457.","journal-title":"N Engl J Med"},{"key":"3175_CR5","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1157\/13111687","volume":"30","author":"F Fuster","year":"2007","unstructured":"Fuster F, Medina L, Vallansot R, Granell M, Brugeuera M: Imatinib induced toxic hepatitis: description of two cases and review of the literature. Gastroenterol Hepatol. 2007, 30: 525-530. 10.1157\/13111687.","journal-title":"Gastroenterol Hepatol"},{"key":"3175_CR6","doi-asserted-by":"publisher","first-page":"1928","DOI":"10.1182\/blood.V99.6.1928","volume":"99","author":"M Talpaz","year":"2002","unstructured":"Talpaz M, Silver RT, Druker BJ, Goldman JM, Gambacorti-Passerini C, Guilhot F, Schiffer CA, Fischer T, Deininger MW, Lennard AL, Hochhaus A, Ottmann OG, Gratwohl A, Baccarani M, Stone R, Tura S, Mahon FX, Fernandes-Reese S, Gathmann I, Capdeville R, Kantarjian HM, Sawyers CL: Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. Blood. 2002, 99: 1928-1937. 10.1182\/blood.V99.6.1928.","journal-title":"Blood"},{"key":"3175_CR7","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker BJ, Talpaz M, Resta DJ, Peng B, Buchdunger E, Ford JM, Lydon NB, Kantarjian H, Capdeville R, Ohno-Jones S, Sawyers CL: Efficacy and safety of a specific inhibitor of the BCRABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001, 344: 1031-1037. 10.1056\/NEJM200104053441401.","journal-title":"N Engl J Med"},{"key":"3175_CR8","first-page":"935","volume":"8","author":"MH Cohen","year":"2002","unstructured":"Cohen MH, Williams G, Johnson JR, Duan J, Gobburu J, Rahman A, Benson K, Leighton J, Kim SK, Wood R, Rothmann M, Chen G, KM U, Staten AM, Pazdur R: Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia. Clin Cancer Res. 2002, 8: 935-942.","journal-title":"Clin Cancer Res"},{"key":"3175_CR9","doi-asserted-by":"crossref","first-page":"6608","DOI":"10.3748\/wjg.v13.i48.6608","volume":"13","author":"Ezequiel Ridruejo","year":"2007","unstructured":"Ridruejo Ezequiel, Cacchione Roberto, Villamil Alejandra G, Marciano Sebasti\u00e1n, Gadano Adri\u00e1n C, Mand\u00f3 Oscar G: Imatinib-induced fatal acute liver failure. World J Gastroenterol. 2007, 13: 6608-6611.","journal-title":"World J Gastroenterol"},{"key":"3175_CR10","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1007\/s12032-009-9284-y","volume":"27","author":"O Tonyali","year":"2010","unstructured":"Tonyali O, Coskun U, Yildiz R, Karakan T, Demirci U, Akyurek N, Benekli M, Buyukberber S: Imatinib mesylate-induced acute liver failure in a patient with gastrointestinal stromal tumors. Med Oncol. 2010, 27: 768-773. 10.1007\/s12032-009-9284-y.","journal-title":"Med Oncol"},{"key":"3175_CR11","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1097\/01.meg.0000216941.42306.0e","volume":"18","author":"A Pariente","year":"2006","unstructured":"Pariente A, Etcharry F, Cales V, Laborde Y, Ferrari S, Biour M: Imatinib mesylate-induced acute hepatitis in a patient treated for gastrointestinal stromal tumour. Eur J Gastroenterol Hepatol. 2006, 18: 785-787. 10.1097\/01.meg.0000216941.42306.0e.","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"3175_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1159\/000111092","volume":"118","author":"JH Kong","year":"2007","unstructured":"Kong JH, Yoo SH, Lee KE, Nam SH, Kwon JM, Lee SM, Chang HJ, Choi MY, Cho MS, Mun YC, Nam E, Lee SN, Seong CM: Early imatinib-mesylate-induced hepatotoxicity in chronic myelogenous leukaemia. Acta Haematol. 2007, 118: 205-208. 10.1159\/000111092.","journal-title":"Acta Haematol"},{"key":"3175_CR13","doi-asserted-by":"publisher","first-page":"e50","DOI":"10.1200\/JCO.2010.30.5359","volume":"29","author":"V Spataro","year":"2011","unstructured":"Spataro V: Nilotinib in a patient with postnecrotic liver cirrhosis related to imatinib. J Clin Oncol. 2011, 29: e50-e52. 10.1200\/JCO.2010.30.5359.","journal-title":"J Clin Oncol"},{"key":"3175_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ctrv.2010.04.008","volume":"37","author":"H Joensuu","year":"2001","unstructured":"Joensuu H, Trent JC, Reichardt P: Practical management of tyrosine kinase inhibitor-associated side effects in GIST. Canc Treat Rev. 2001, 37: 75-88.","journal-title":"Canc Treat Rev"},{"key":"3175_CR15","doi-asserted-by":"publisher","first-page":"3152","DOI":"10.1002\/cncr.25071","volume":"116","author":"WG Tong","year":"2010","unstructured":"Tong WG, Kantarjian H, O'Brien S, Faderl S, Ravandi F, Borthakur G, Shan J, Pierce S, Rios MB, Cortes J: Imatinib front-line therapy is safe and effective in patients with chronic myelogenous leukemia with pre-existing liver and\/or renal dysfunction. Cancer. 2010, 116: 3152-3159. 10.1002\/cncr.25071.","journal-title":"Cancer"},{"key":"3175_CR16","doi-asserted-by":"publisher","first-page":"563","DOI":"10.1200\/JCO.2007.11.0304","volume":"26","author":"RK Ramanathan","year":"2008","unstructured":"Ramanathan RK, Egorin MJ, Takimoto CH, Remick SC, Doroshow JH, LoRusso PA, Mulkerin DL, Grem JL, Hamilton A, Murgo AJ, Potter DM, Belani CP, Hayes MJ, Peng B, Ivy SP, National Cancer Institute Organ Dysfunction Working Group: Phase I and pharmacokinetic study of imatinib mesylate in patients with advanced malignancies and varying degrees of liver dysfunction: a study by the National Cancer Institute Organ Dysfunction Working Group. J Clin Oncol. 2008, 26: 563-569. 10.1200\/JCO.2007.11.0304.","journal-title":"J Clin Oncol"},{"issue":"12","key":"3175_CR17","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/j.ultrasmedbio.2003.07.001","volume":"29","author":"L Sandrin","year":"2003","unstructured":"Sandrin L, Fourquet B, Hasquenoph JM, Yon S, Fournier C, Mal F, Christidis C, Ziol M, Poulet B, Kazemi F, Beaugrand M, Palau R: Transient elastography: a new noninvasive method for assessment of hepatic fibrosis. Ultrasound Med Biol. 2003 Dec, 29 (12): 1705-1713. 10.1016\/j.ultrasmedbio.2003.07.001.","journal-title":"Ultrasound Med Biol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-186.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/1471-2407-12-186\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/1471-2407-12-186","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,28]],"date-time":"2019-06-28T23:49:47Z","timestamp":1561765787000},"score":1,"resource":{"primary":{"URL":"http:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/1471-2407-12-186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,5,21]]},"references-count":17,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,12]]}},"alternative-id":["3175"],"URL":"https:\/\/doi.org\/10.1186\/1471-2407-12-186","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,5,21]]},"article-number":"186"}}